Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population
PRECISION1 tumor-agnostic trial.
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) Chairman Neil Desai sold 25,569 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $4.37, for a total value of $111,736.53. Following the transaction, the chairman now directly owns 1,637,974 shares of the company’s stock, […]
/PRNewswire/ Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients.